CERo Therapeutics

Q2 FY2026 EarningsCERO reported a Q2 FY26 Net Loss of $1.03M, significantly beating the consensus mean estimate of $6.47M. Despite the bottom-line beat driven by non-cash gains on preferred stock liabilities, EPS GAAP of -$0.70 beat expectations of -$1.04. Revenue remains at $0 as expected for this clinical-stage biotech. The company continues to face severe liquidity challenges with substantial doubt about its ability to continue as a going concern, underscored by a $30.9M working capital deficit.